- Home
- TOPS vs NXTC Comparison
TOPS vs NXTC Comparison
Compare TOPS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- NXTC
- Stock Information
- Founded
- TOPS 2000
- NXTC 2015
- Country
- TOPS Greece
- NXTC United States
- Employees
- TOPS N/A
- NXTC N/A
- Industry
- TOPS Marine Transportation
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- NXTC Health Care
- Exchange
- TOPS Nasdaq
- NXTC Nasdaq
- Market Cap
- TOPS 31.1M
- NXTC 31.6M
- IPO Year
- TOPS 2004
- NXTC 2019
- Fundamental
- Price
- TOPS $6.73
- NXTC $0.82
- Analyst Decision
- TOPS
- NXTC Strong Buy
- Analyst Count
- TOPS 0
- NXTC 2
- Target Price
- TOPS N/A
- NXTC $4.00
- AVG Volume (30 Days)
- TOPS 14.6K
- NXTC 309.4K
- Earning Date
- TOPS 01-14-2025
- NXTC 11-07-2024
- Dividend Yield
- TOPS N/A
- NXTC N/A
- EPS Growth
- TOPS N/A
- NXTC N/A
- EPS
- TOPS N/A
- NXTC N/A
- Revenue
- TOPS $83,870,000.00
- NXTC N/A
- Revenue This Year
- TOPS $7.10
- NXTC N/A
- Revenue Next Year
- TOPS $6.54
- NXTC N/A
- P/E Ratio
- TOPS N/A
- NXTC N/A
- Revenue Growth
- TOPS 1.10
- NXTC N/A
- 52 Week Low
- TOPS $5.30
- NXTC $0.76
- 52 Week High
- TOPS $15.91
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- TOPS 53.31
- NXTC 31.28
- Support Level
- TOPS $5.75
- NXTC $0.76
- Resistance Level
- TOPS $6.21
- NXTC $0.93
- Average True Range (ATR)
- TOPS 0.39
- NXTC 0.09
- MACD
- TOPS 0.11
- NXTC -0.01
- Stochastic Oscillator
- TOPS 100.00
- NXTC 16.89
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.